CA2554465A1 - Piperidine derivatives useful as ccr3 antagonists - Google Patents
Piperidine derivatives useful as ccr3 antagonists Download PDFInfo
- Publication number
- CA2554465A1 CA2554465A1 CA002554465A CA2554465A CA2554465A1 CA 2554465 A1 CA2554465 A1 CA 2554465A1 CA 002554465 A CA002554465 A CA 002554465A CA 2554465 A CA2554465 A CA 2554465A CA 2554465 A1 CA2554465 A1 CA 2554465A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- hydrogen
- mmol
- cr20r21
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54201304P | 2004-02-05 | 2004-02-05 | |
| US60/542,013 | 2004-02-05 | ||
| PCT/US2005/002664 WO2005077369A1 (en) | 2004-02-05 | 2005-02-02 | Piperidine derivatives useful as ccr3 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2554465A1 true CA2554465A1 (en) | 2005-08-25 |
Family
ID=34860249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002554465A Abandoned CA2554465A1 (en) | 2004-02-05 | 2005-02-02 | Piperidine derivatives useful as ccr3 antagonists |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7705153B2 (https=) |
| EP (1) | EP1725235B1 (https=) |
| JP (1) | JP2007520556A (https=) |
| CN (1) | CN1946402A (https=) |
| AT (1) | ATE428422T1 (https=) |
| CA (1) | CA2554465A1 (https=) |
| DE (1) | DE602005013931D1 (https=) |
| ES (1) | ES2324224T3 (https=) |
| WO (1) | WO2005077369A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006100190A (ru) * | 2003-06-13 | 2006-08-10 | Шеринг Акциенгезельшафт (De) | Производные хинолиламида в качестве антагонистов ccr-5 |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| TW200803855A (en) * | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| CN101460482B (zh) * | 2006-03-21 | 2013-03-27 | 默沙东公司 | 具有cxcr3拮抗剂活性的杂环取代的吡啶化合物 |
| MX2009000577A (es) * | 2006-07-14 | 2009-03-09 | Schering Corp | Compuestos de piperazina sustituida heterociclica con actividad antagonista de cxcr3. |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| WO2012171863A1 (en) * | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| EP2780015B1 (en) | 2011-11-18 | 2017-01-04 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| KR20160098424A (ko) | 2013-12-19 | 2016-08-18 | 바이엘 파마 악티엔게젤샤프트 | 치환된 피페리디닐-테트라히드로퀴놀린 |
| EP3083610A1 (de) | 2013-12-19 | 2016-10-26 | Bayer Pharma Aktiengesellschaft | Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten |
| CR20160276A (es) | 2013-12-19 | 2016-10-20 | Bayer Pharma AG | "piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c" |
| US20160318866A1 (en) | 2013-12-19 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| CN110636844A (zh) | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| PL233595B1 (pl) | 2017-05-12 | 2019-11-29 | Celon Pharma Spolka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US20230312697A1 (en) | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| US12221463B2 (en) | 2020-08-07 | 2025-02-11 | The Board Of Regents Of The University Of Oklahoma | Method of promoting wound healing by inhibiting CCR3 |
| CN112250611B (zh) * | 2020-11-27 | 2022-04-22 | 济南大学 | 一种-2-(2,5-二氟苯基)吡咯烷盐酸盐的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| KR0171169B1 (ko) * | 1996-01-20 | 1999-03-30 | 구자홍 | 엘시디 패널 구동을 위한 다계조 전압 발생 회로 |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| SK287418B6 (sk) * | 1999-05-04 | 2010-09-07 | Schering Corporation | Farmaceutický prípravok s obsahom CCR5 antagonistov a súprava s obsahom tohto prípravku |
| AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| JP4303969B2 (ja) * | 2001-03-29 | 2009-07-29 | シェーリング コーポレイション | Ｃｃｒ５アンタゴニストとして有用なアリールオキシム−ピペラジン |
| AR033452A1 (es) * | 2001-03-29 | 2003-12-17 | Schering Corp | Antagonistas de ccr5 utiles para el tratamiento del sida |
-
2005
- 2005-02-02 CA CA002554465A patent/CA2554465A1/en not_active Abandoned
- 2005-02-02 AT AT05712200T patent/ATE428422T1/de not_active IP Right Cessation
- 2005-02-02 US US11/049,460 patent/US7705153B2/en not_active Expired - Fee Related
- 2005-02-02 WO PCT/US2005/002664 patent/WO2005077369A1/en not_active Ceased
- 2005-02-02 JP JP2006552160A patent/JP2007520556A/ja active Pending
- 2005-02-02 EP EP05712200A patent/EP1725235B1/en not_active Expired - Lifetime
- 2005-02-02 CN CNA2005800121378A patent/CN1946402A/zh active Pending
- 2005-02-02 ES ES05712200T patent/ES2324224T3/es not_active Expired - Lifetime
- 2005-02-02 DE DE602005013931T patent/DE602005013931D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1946402A (zh) | 2007-04-11 |
| JP2007520556A (ja) | 2007-07-26 |
| US20050182095A1 (en) | 2005-08-18 |
| WO2005077369A1 (en) | 2005-08-25 |
| ATE428422T1 (de) | 2009-05-15 |
| ES2324224T3 (es) | 2009-08-03 |
| US7705153B2 (en) | 2010-04-27 |
| EP1725235A1 (en) | 2006-11-29 |
| DE602005013931D1 (https=) | 2009-05-28 |
| EP1725235B1 (en) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2554465A1 (en) | Piperidine derivatives useful as ccr3 antagonists | |
| JP4025200B2 (ja) | ピペリジンｍｃｈアンタゴニストおよび肥満の処置におけるそれらの使用 | |
| ES2241997T3 (es) | Antagonistas de la mch y su uso en el tratamiento de la obesidad. | |
| TWI290555B (en) | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | |
| AU2002350269B2 (en) | Piperidine -based MCH antagonists for treatment of obesity and CNS disorders | |
| TWI545121B (zh) | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體致效劑活性之化合物 | |
| JP4758609B2 (ja) | γ−セクレターゼ阻害剤 | |
| HK1247610A1 (en) | Piperidine derivatives as nk1 antagonists | |
| TW200800182A (en) | Nitrogen-containing heterocyclic derivatives substituted by ring-type groups | |
| CA2787248C (en) | Piperazine compound having a pgds inhibitory effect | |
| WO2004009555A1 (ja) | ５−置換イソキノリン誘導体 | |
| JP2004503547A (ja) | セリンプロテアーゼインヒビター | |
| AU2002357885A1 (en) | Compounds for the treatment of inflammatory disorders | |
| JP4458853B2 (ja) | Ｎｋ１アンタゴニスト | |
| TW200302719A (en) | MCH antagonists for the treatment of obesity | |
| JP2013521250A (ja) | アミノインダンの誘導体、これらの調製および治療におけるこれらの適用 | |
| EP2274295A1 (en) | 3, 4 - substituted piperidine derivatives as renin inhibitors | |
| JP4464280B2 (ja) | エリスロポエチン産生促進剤 | |
| JP2005522492A (ja) | 癌治療薬 | |
| CA2526725A1 (en) | Mch antagonists for the treatment of obesity | |
| CA2562138A1 (en) | Fused ring nk1 antagonists | |
| MXPA06009006A (en) | Piperidine derivatives useful as ccr3 antagonists | |
| TW202547516A (zh) | 稠合雙環化合物及其用途 | |
| AU2017201251A1 (en) | Piperidine derivatives as nk1 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |